A Move To Shift Part B Rx Into Part D Would Anger Oncologists, Cancer Patients

By John Wilkerson / May 19, 2017 at 7:12 PM

If the administration were to propose shifting drugs covered by Medicare Part B into the Part D drug reimbursement system, the move would spark a blitz of opposition from cancer doctors and patients, and hospitals might also push back hard if the policy were accompanied by changes to the 340B drug discount program, lobbyists say.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.